Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A.
about
Role of Phosphodiesterase 5 and Cyclic GMP in HypertensionObesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failureThe crystal structure of the catalytic domain of a eukaryotic guanylate cyclaseATP-independent activation of natriuretic peptide receptorsCalcium-dependent dephosphorylation mediates the hyperosmotic and lysophosphatidic acid-dependent inhibition of natriuretic peptide receptor-B/guanylyl cyclase-BImplication of microRNAs in atrial natriuretic peptide and nitric oxide signaling in vascular smooth muscle cellsSpare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular systemAlternative splicing of the guanylyl cyclase-A receptor modulates atrial natriuretic peptide signalingStress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase IVentricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome.Innovative Therapeutics: Designer Natriuretic Peptides.Context-independent essential regulatory interactions for apoptosis and hypertrophy in the cardiac signaling networkNovel functions of photoreceptor guanylate cyclases revealed by targeted deletionEvidence for cross-talk between atrial natriuretic peptide and nitric oxide receptorsVascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptideBNP controls early load-dependent regulation of SERCA through calcineurin.A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway.Impact of obesity on the expression profile of natriuretic peptide system in a rat experimental model.Grueneberg ganglion olfactory subsystem employs a cGMP signaling pathway.Genetic variation in the natriuretic peptide system and heart failure.Guanylyl cyclases A and B are asymmetric dimers that are allosterically activated by ATP binding to the catalytic domain.A cardiac pathway of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor for atrial natriuretic peptideAgents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle.Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway.Heterogeneous nuclear ribonucleoprotein A1 is a novel cellular target of atrial natriuretic peptide signaling in renal epithelial cells.Cyclic guanosine monophosphate compartmentation in rat cardiac myocytesSynthetic Peptides as cGMP-Independent Activators of cGMP-Dependent Protein Kinase IαRecombinant Atrial Natriuretic Peptide Prevents Aberrant Ca2+ Leakage through the Ryanodine Receptor by Suppressing Mitochondrial Reactive Oxygen Species Production Induced by Isoproterenol in Failing Cardiomyocytes.Endothelial actions of atrial and B-type natriuretic peptidesCardiovascular and metabolic effects of natriuretic peptides.Natriuretic peptides enhance the oxidative capacity of human skeletal muscle.Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.Disruption of guanylyl cyclase-G protects against acute renal injuryThe heart communicates with the endothelium through the guanylyl cyclase-A receptor: acute handling of intravascular volume in response to volume expansionDesign, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.The natriuretic peptide/guanylyl cyclase--a system functions as a stress-responsive regulator of angiogenesis in miceCinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload.Morphological and molecular changes of the myocardium after left ventricular mechanical supportRenin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
P2860
Q26748049-D1811C8B-490C-4028-BBBE-3808F0147B14Q27027081-830B8615-21ED-44C4-85E0-5887E929FF77Q27652454-F108590E-17AB-4789-83C8-F908E9DE3F9BQ28252448-B3DF2C10-0C7F-4B58-9E1C-6EE23B2336CFQ28282496-0769F21C-D866-44A6-A63F-382CE9284EC7Q28392601-97654723-B915-4222-A0C1-0BD87692555CQ28513504-8E83CDBD-7429-4B76-A0DF-3178CBF4005BQ30371510-AF404638-6292-4D9E-A2DB-800E618A0132Q30539041-4AEA598B-27C2-4168-848C-8D40A9291BBBQ30548444-EE39EC42-0FF2-4D15-B38C-D37F73652205Q33569817-6E1894F8-7886-4B7B-9F4E-F1BC954EDE36Q33653332-63FF1E4C-E8E8-40C4-84F5-26342C7CE408Q33671530-8708C077-7AA9-4761-B689-118138551733Q33706821-44918B02-EF88-4237-A174-94CA632E355BQ33824523-DFCC9ED7-EE7A-414E-93D7-3F4A6AD4B88DQ33831907-329F285B-8F51-43ED-9103-2DAA360DB7F1Q34247492-A7774C46-EF3D-406C-A2B2-922D2C4AC787Q34275631-2D27DA48-482B-40D1-B2CD-048BFA2D3B38Q34979675-051422C5-4120-4A7E-BF8C-BBCC366C5F4DQ35039266-8C148D66-2CFF-4860-993A-E63F56B37D69Q35046791-6541D4F2-740F-4004-981F-4C721F289CD5Q35543592-20260D2B-FFEF-41E1-B1F3-125798B5B339Q35546884-3EA51F86-EC4F-423B-92B2-5DFB66B3B285Q35563508-0E3F77A8-A1CD-4C18-8F15-BF57F0EF96D1Q35624678-5497BDEF-B312-4DCB-B4C5-192F6267924CQ35783161-3357037A-C24D-4914-B8E1-2DCE9D0035EFQ35812341-93860E11-496D-4330-B1AD-0BB47C6CCAEDQ35873815-413B9AA7-F2F2-4232-BF07-7E362494BC06Q36140769-ED2763B0-738C-43BE-85BE-15467FFFAF8BQ36159149-2201A3EA-3CB6-486B-828E-BD1AC1880FA1Q36382621-3A1A7E68-0780-4E46-BB98-597C3FA277CAQ36498070-ACD82DD1-BE0B-4F80-A3D4-962F9091730EQ36512551-18541CE7-0A6B-4B31-8F26-B64D4AD4B625Q36677353-9FAC89E3-4EB0-4AC0-89D6-9AEB12D26BA3Q36796605-B35B1A14-2B54-4664-9DB4-2DA52A6DAE3CQ36954799-8CD62EDA-0999-48DE-A128-7BA63CDBEBF7Q37241365-7C2EBDEA-D81F-4A0E-8A57-3C1617F36D82Q37419185-FCEA9207-FFE0-431A-BB37-D75EA96DD85BQ37638247-9C4B7530-6842-451C-9A70-87E28A68299BQ37694008-562F22BE-0D4B-4B04-A9BD-E4AF98549459
P2860
Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Structure, regulation, and fun ...... a focus on guanylyl cyclase-A.
@ast
Structure, regulation, and fun ...... a focus on guanylyl cyclase-A.
@en
type
label
Structure, regulation, and fun ...... a focus on guanylyl cyclase-A.
@ast
Structure, regulation, and fun ...... a focus on guanylyl cyclase-A.
@en
prefLabel
Structure, regulation, and fun ...... a focus on guanylyl cyclase-A.
@ast
Structure, regulation, and fun ...... a focus on guanylyl cyclase-A.
@en
P1433
P1476
Structure, regulation, and fun ...... a focus on guanylyl cyclase-A.
@en
P2093
Michaela Kuhn
P304
P356
10.1161/01.RES.0000094745.28948.4D
P577
2003-10-01T00:00:00Z